ReCOV (recombinant two-component COVID-19 vaccine (CHO cell)) / Jiangsu Rec-Biotech - LARVOL DELTA

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov) (clinicaltrials.gov) - P3 | N=7623 | Completed | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov) (clinicaltrials.gov) - P3 | N=7623 | Active, not recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Trial primary completion date: Jun 2023 ➔ Sep 2023

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov) (clinicaltrials.gov) - P3 | N=7623 | Active, not recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Aug 2023 ➔ Nov 2023

Enrollment closed • Trial completion date • Infectious Disease • Novel Coronavirus Disease

ReCOV: Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (clinicaltrials.gov) - P2 | N=948 | Completed | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) (clinicaltrials.gov) - P2 | N=300 | Completed | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Recruiting ➔ Completed | Phase classification: P2/3 ➔ P2

Phase classification • Trial completion • Infectious Disease • Novel Coronavirus Disease

ReCOV: Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (clinicaltrials.gov) - P2 | N=947 | Recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting | Phase classification: P2/3 ➔ P2 | N=20301 ➔ 947 | Trial completion date: Dec 2023 ➔ Mar 2023 | Trial primary completion date: Dec 2022 ➔ Aug 2022

Enrollment change • Enrollment open • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) (clinicaltrials.gov) - P2/3 | N=300 | Recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Active, not recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease

Safety, Reactogenicity and Immunogenicity Study of ReCOV (clinicaltrials.gov) - P1 | N=100 | Completed | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Mar 2023 ➔ May 2022 | Trial primary completion date: Nov 2022 ➔ May 2022

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CD4 • IL17A

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) (clinicaltrials.gov) - P2/3 | N=300 | Active, not recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Not yet recruiting ➔ Active, not recruiting | N=1950 ➔ 300 | Trial primary completion date: Feb 2023 ➔ Aug 2022

Enrollment change • Enrollment closed • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov) (clinicaltrials.gov) - P3 | N=10000 | Not yet recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Initiation date: May 2022 ➔ Sep 2022

Trial initiation date • Infectious Disease • Novel Coronavirus Disease

Efficacy, Safety and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)(Recov) (clinicaltrials.gov) - P3 | N=10000 | Not yet recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd.

New P3 trial • Infectious Disease • Novel Coronavirus Disease

Safety, Reactogenicity and Immunogenicity Study of ReCOV (clinicaltrials.gov) - P1 | N=99 | Active, not recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd. | Trial completion date: Jul 2022 ➔ Mar 2023 | Trial primary completion date: Dec 2021 ➔ Nov 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CD4 • IFNG • IL17A

Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV) (clinicaltrials.gov) - P2/3 | N=1950 | Not yet recruiting | Sponsor: Jiangsu Rec-Biotechnology Co., Ltd.

New P2/3 trial • Infectious Disease • Novel Coronavirus Disease

Safety, Reactogenicity and Immunogenicity Study of ReCOV (clinicaltrials.gov) - P1; N=99; Active, not recruiting; Sponsor: Jiangsu Rec-Biotechnology Co., Ltd.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • CD4 • IFNG • IL17A • PCR

Safety, Reactogenicity and Immunogenicity Study of ReCOV (clinicaltrials.gov) - P1; N=100; Recruiting; Sponsor: Jiangsu Rec-Biotechnology Co., Ltd.; N=160 ➔ 100

Clinical • Enrollment change • Infectious Disease • Novel Coronavirus Disease • CD4 • IFNG • IL17A • PCR

ReCOV: Efficacy, Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) (clinicaltrials.gov) - P2/3; N=20301; Not yet recruiting; Sponsor: Jiangsu Rec-Biotechnology Co., Ltd.

Clinical • New P2/3 trial • Infectious Disease • Novel Coronavirus Disease

Safety, Reactogenicity and Immunogenicity Study of ReCOV (clinicaltrials.gov) - P1; N=160; Recruiting; Sponsor: Jiangsu Rec-Biotechnology Co., Ltd.; Trial primary completion date: Jul 2021 ➔ Dec 2021

Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • CD4 • IFNG • IL17A • PCR

Safety, Reactogenicity and Immunogenicity Study of ReCOV (clinicaltrials.gov) - P1; N=160; Recruiting; Sponsor: Jiangsu Rec-Biotechnology Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease • CD4 • IFNG • IL17A • PCR